These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 23328275)

  • 1. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
    Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
    Brand T; Macha S; Mattheus M; Pinnetti S; Woerle HJ
    Adv Ther; 2012 Oct; 29(10):889-99. PubMed ID: 23054692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
    Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
    Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.
    Macha S; Dieterich S; Mattheus M; Seman LJ; Broedl UC; Woerle HJ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):132-40. PubMed ID: 23253948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.
    Macha S; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Diabetes Obes Metab; 2013 Apr; 15(4):316-23. PubMed ID: 23094794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.
    Macha S; Mattheus M; Pinnetti S; Broedl UC; Woerle HJ
    Clin Ther; 2015 Jul; 37(7):1503-16. PubMed ID: 26051874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet
.
    Glund S; Mattheus M; Runge F; Rose P; Friedrich C
    Int J Clin Pharmacol Ther; 2017 Apr; 55(4):355-367. PubMed ID: 28290274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial.
    Friedrich C; Jungnik A; Retlich S; Ring A; Meinicke T
    Drug Res (Stuttg); 2014 May; 64(5):269-75. PubMed ID: 24154935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
    Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
    Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.
    Macha S; Koenen R; Sennewald R; Schöne K; Hummel N; Riedmaier S; Woerle HJ; Salsali A; Broedl UC
    Clin Ther; 2014 Feb; 36(2):280-90.e1. PubMed ID: 24491572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.
    Graefe-Mody U; Giessmann T; Ring A; Iovino M; Woerle HJ
    Clin Ther; 2011 Aug; 33(8):1096-103. PubMed ID: 21803422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.
    Macha S; Lang B; Pinnetti S; Broedl UC
    Int J Clin Pharmacol Ther; 2014 Nov; 52(11):973-80. PubMed ID: 25161155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
    Tan X; Hu J
    Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
    Rizos CV; Filippatos TD; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
    Macha S; Rose P; Mattheus M; Cinca R; Pinnetti S; Broedl UC; Woerle HJ
    Diabetes Obes Metab; 2014 Feb; 16(2):118-23. PubMed ID: 23859534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects.
    Macha S; Brand T; Meinicke T; Link J; Broedl UC
    Clin Ther; 2015 Aug; 37(8):1789-96. PubMed ID: 26138865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
    Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
    Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.